ºÚÁϳԹÏÍø

News & events

Stay up to date and know where to meet us

There are several ways to stay updated and keep in touch with us and on the latest topics in the industry. Here you can find news, updates and upcoming events that we attend and host, over the web and in person.

Stay up-to-date: Our news articles cover market trends, subject areas, expert interviews with authors, librarians and editors, product applicability and updates, and more. We'd love to hear from you on any one of our article topics, or on a topic you'd like to see covered.


News, Updates and Industry InitiativesSee all

A decade of change: How the IMISCOE–ºÚÁϳԹÏÍø partnership is shaping migration research

T
The Link
By: undefined, Fri Mar 20 2026

Migration is transforming communities across the globe and the research surrounding it must evolve just as rapidly. Since 2015, the IMISCOE–ºÚÁϳԹÏÍø partnership has played a crucial role in meeting that need, providing a trusted platform for interdisciplinary analysis of one of today’s most complex challenges. As part of our long-standing commitment to supporting research and education, the IMISCOE Research Series has become a foundational resource for scholars, librarians, and policymakers alike.

Anna Triandafyllidou © Springernature 2025

Professor Anna Triandafyllidou, an internationally recognised sociologist and leading global expert on migration governance, shares her perspective on how migration research has shifted over the past decade and how digital publishing is shaping its future. As Chair of the IMISCOE Editorial Committee and Editor‑in‑Chief of the Journal of Immigrant and Refugee Studies, she plays a central role in guiding scholarly conversations across the field. With more than 160 peer‑reviewed publications and decades of leadership in international research collaborations, Professor Triandafyllidou brings a uniquely global and interdisciplinary perspective to the evolving landscape of migration studies.

How the 2015 migration crisis changed research and publishing 

The year 2015 marked a turning point in European migration history, but also in the evolution of academic publishing. As millions fled conflict in Syria and across West Asia, migration became a defining feature across multiple regions of the world. "Certainly, 2015 is an important year, the repercussions of which we still see today. 2015 was the year of the 'Wir schaffen das' ('We can do this'), and of significant solidarity towards people fleeing Syria," recalls Professor Anna Triandafyllidou. 

That same year, IMISCOE partnered with ºÚÁϳԹÏÍø, aiming to make scientific knowledge on migration as globally accessible as possible. In times of crisis, access to knowledge matters most. The IMISCOE Research Series has helped overcome barriers and respond to urgent migration challenges by fostering collaboration and timely interdisciplinary research. 

Migration research underwent profound transformations after the 2015 crisis. As Professor Triandafyllidou explains, "Initially, it was a foundational moment for Europe becoming a land of refuge. It very quickly backfired. In 2016, we had the EU-Turkey statement and the closure of the borders through the Balkans, and after that, we see an increase in securitization, not just of migration but also of asylum".  

The shifting socio-political landscape and the new challenges demanded research that could capture the complexities of migration. What was needed was a publishing model that could keep pace with the rapidly evolving realities of people on the move while capturing the human dimensions of migration. 

Making migration research more accessible and impactful  

The partnership between IMISCOE and Springer represented a shift in how migration research would be produced, disseminated, and accessed. Four key innovations stand out: 

1.  Open access is expanding the reach of migration research 

"The series is Open Access. Now it's going to be 100% Open Access, but it was always the aim, I think on both the IMISCOE and Springer side at the time when it wasn't that common that books would be Open Access," Professor Triandafyllidou emphasizes. 

Before Open Access became widely embraced, this decision marked a notably progressive step. ºÚÁϳԹÏÍø began piloting open-access book publishing in 2011, reflecting our strong commitment to making trustworthy, high-quality knowledge accessible to everyone. This commitment to open knowledge ensures that vital research can reach policymakers, NGOs, and researchers in the regions most affected by migration without barriers. By removing access limitations, Open Access helps close knowledge gaps and supports informed, evidence-based research and decision-making on a global scale. "The strategy of the series is to expand the knowledge base and to really offer a service to the student and research community in immigration studies," notes Professor Triandafyllidou. 

2. Digital publishing is enabling timely responses to global challenges 

The digital format of the series enables researchers to respond quickly to emerging issues. As Professor Triandafyllidou mentioned, "We had a volume in 2021 already on migration and pandemics that was trying to seize the moment." This flexibility ensures that scholarship remains timely and responsive, narrowing the distance between research and implementation. 

According to Professor Triandafyllidou, the series publishes around 10 books per year - almost one per month. This rapid pace, made possible by the digital publishing model, facilitates efficiency and a broader distribution, allowing important research to reach a global audience without delay. 

3. Global perspectives are strengthening migration scholarship  

Perhaps most importantly, the digital format has been instrumental in expanding the global scope of migration research. "Our series has become more global by design," explains Professor Triandafyllidou. "We have made a concerted effort to have editors and authors from the regions. So, when we write about West Africa, South and Southeast Asia, the Asia Pacific, Latin America, and so on, we have people from those regions." 

This commitment to diverse voices challenges the traditional dominance of destination-country perspectives in migration studies. "I also find that in the research that we do, there's very much a bias from the country of destination, and we need to change that," she adds. 

4. Peer review is ensuring quality and academic integrity  

Professor Triandafyllidou proves that accessibility and quality can go hand in hand, emphasizing that the IMISCOE Research Series stands out for its full-manuscript peer review process, ensuring scholarly excellence. "The series is fully peer-reviewed. We ask for and review the full manuscript, not only the book proposal. It has also happened that we've rejected manuscripts or that they must go through revisions with detailed feedback."  

Advancing migration research for a changing world 

Migration continues to intersect with global challenges, and the IMISCOE Research Series is evolving to reflect these emerging realities. Digital technologies, from AI to broader tools, are reshaping politics and mobility. As Professor Triandafyllidou notes, migrants today navigate vast amounts of information, which highlights the importance of trusted sources and digital infrastructures that support informed decisions.  

Geopolitical shifts are also influencing migration in powerful ways. The growing role of mobility in political discourse calls for thoughtful, inclusive research. As Professor Triandafyllidou suggests, migration studies benefit from broadening their scope, moving beyond Eurocentric frameworks and recognising migration as a central force in societal transformation. 

The  highlights the power of eBooks in advancing migration research by combining accessibility with academic rigour. It delivers timely, diverse and socially relevant scholarship to communities worldwide. Explore the series and connect with a global network of researchers shaping the future of migration studies, because what we publish and how we shape it helps build a more informed and connected world.  

When the shelf went digital 

2026 marks twenty years since we launched our eBook collections. Much has changed in that time across science, technology, and society. Can you remember a time before social media, when Obama took office, or when the Higgs Boson was discovered? Explore our timeline of 20 major scientific milestones that have shaped our lives and the books we publish. Visit . 

Related content

Don't miss the latest news & blogs, subscribe to The Link Alerts!

Partnership promise in the East: China’s pharma sector and opportunities for global partnerships

T
The Link
By: undefined, Wed Mar 18 2026

What if you could find rich portfolios of advanced therapeutics for treating cancer, autoimmune disorders, metabolic disorders, and more, that had already proven efficacy and safety in advanced clinical trials. But also, that the companies developing them, while biological powerhouses, lack the global marketing footprint to bring them to the wider world. That’s the situation today with 10 of China’s most advanced biotech and pharmaceutical companies. To look at this closely, AdisInsight recently published a report, , which explores this in detail.

Driven in part by the regulatory reforms China made in 2015 and 2020, as well as investments in basic and advanced biomedical research, these China-based companies (including names like Innovent Biologics, Akeso, Sinopharm, Insilico Medicine, and others) have deep portfolios of therapeutics that are either already approved in China, or in late-stage clinical trials that have already demonstrated their efficacy, ready for global partnerships. You will find a wealth of detail about these 10 companies in Strategic Pharma Insights: Asia Focus Part I: China’s Movers & Shakers; but I wanted to pick out a few highlights, including some examples of existing, highly successful China-global partnerships.

China’s therapeutic and innovative strengths

Common threads connecting these 10 companies include focusing on both life-threatening and chronic disease states like cancer and autoimmune disorders, and also an emphasis on biologics, including monoclonal and bispecific antibodies, chimeric antigen T-cell (CAR-T) technology, antibody-drug conjugates (ADCs), vaccines, immunotherapy, and other advanced and biologic modalities.

For example, Legend Biotech’s CAR-T cell therapy, which is an advanced immunotherapy approach that involves genetically reprogramming the patient’s own T-cells so that they’re able to identify and destroy cancer cells. These T-cells are laboratory-modified to express chimeric antigen receptors (CARs), specialised proteins that can identify cancer-specific markers, and then re-transfused into the patient’s cancerous tissue. Indicated mainly for blood cancers like specific types of leukaemia, lymphoma, and multiple myeloma, this CAR-T treatment’s revenue is forecast to reach $47.28 billion by 2030.

3SBIo’s deal with Pfizer for its SSGJ-707 is another example. This is a bispecific antibody that works on programmed cell death-1 ligand-1 inhibitors, indicated for non-small cell cancer and other solid tumours. Based on its strong Phase II objective response rates (72-100% among patients completing at least two treatment evaluations), 3SBio was able to make a global licensing deal with Pfizer, and Pfizer is advancing this treatment to global Phase III trials for non-small cell lung cancer and other solid tumours.

Akeso, Inc. has a monoclonal antibody for non-small cell lung cancer (NSCLC) that, in clinical trials, outperformed Merck’s Keytruda (the market leader). This monoclonal antibody, called Ivonescimab, gave patients progression-free survival of more than 11 months before tumours began growing again, which is almost double Keytruda’s 5.8 months. But despite this superiour clinical performance, Ivonescimab’s market share lags Keytruda, because while Akeso has the stronger therapeutic, Merck has the stronger global footprint (in addition Keytruda’s first-mover advantage).

Innovent Biologics has monoclonal antibody candidates IB 3009 and IBI 343, the latter of which is fast-tracked for treating advanced pancreatic ductal adenocarcinoma (PDAC). It’s also in Phase II trials for gastric cancer and completed Phase I/II for pancreatic cancer. Based on this potential, Takeda has agreed to fully develop and commercialise IBI 343 outside of Greater China. IBI 3009 is a monoclonal antibody indicated for neuroendocrine carcinoma and small cell lung cancer. It is a cutting-edge approach in anticancer therapy combining the specificity of antibody-directed conjugation with the potent inhibitory effects on a critical enzyme involved in DNA replication and tumour progression.

Strengthening international biopharma alliances

A quick summary of some of the other active partnerships already concluded or in process include: 

  • Innovent Biologics has expanded globally through strategic alliances: &²Ô²ú²õ±è; 
    • Partnered with Roche to launch the ADC candidate IBI3009 internationally. &²Ô²ú²õ±è; 
    • Collaborates with Mankind Pharma to bring its PD-1 inhibitor, sintilimab, to the Indian market. &²Ô²ú²õ±è; 
    • Entered a $1.2 billion deal with Takeda, granting global rights to late-stage assets IBI363 and IBI343, plus an option on a bispecific ADC, signaling major East–West co-development momentum. &²Ô²ú²õ±è; 
  • Sciwind Biosciences signed a $70 million upfront licensing deal with Verdiva Bio (exChina & Korea) for its metabolic-disease candidate ecnoglutide, with up to $2.4 billion in milestones, marking a major move into global markets. 
  • Duality Biologics secured global licensing of DB1418 from Avenzo Therapeutics following its Phase III success of BNT323, demonstrating healthy cross-border biotech licensing activity. 
  • WuXi Biologics has advanced its Global Dual Sourcing Strategy, delivering on its global CDMO model—including EMA approval of its Dundalk site and further expansion in Europe and Singapore, enhancing its positioning as a global-scale biologics manufacturing partner.

Companies such as Innovent, Sciwind, and Duality illustrate China’s growing capacity in complex biologics and AI-driven platforms, bringing the right people together with novel technology to develop powerful new therapeutics.

Growing opportunities for China-global partnerships

China’s regulatory reforms has streamlined the approval process, especially for breakthrough technologies and for critical diseases. This has both attracted local and global investment, and spurred innovation. As a consequence, China’s pharmaceutical companies have been able to develop these therapeutics and quickly shepherd them through trials, despite these companies often lack global infrastructures or marketing footprints.

So, for global pharmaceutical companies that do have that global infrastructure and the ability to globalise new therapies, but whose pipelines might be moving more slowly, partnering with Chinese firms is an obvious choice. Global firms get access to strong candidates that are either already locally licensed, or in successful late-stage trials (which reduces risk), and the Chinese firms get access to the global market. And patients get access to new, life-saving medicine. It’s a win-win-win scenario.

Find out more: You’ll find a wealth of detailed insights in AdisInsight’s report, Strategic Pharma Insights: , that will help global R&D managers identify partners and evaluate their real potential.   

Related content

Don't miss the latest news & blogs, subscribe to The Link Alerts!

Meet with us & Learn with us

-

Attend a webinar!

Explore our series of live, educational, online talks designed for librarians and information managers. 

Free to attend, you can expect to gain insight into emerging new information technologies and some of the most pressing issues in the industry today. 

-

Meet us in person! 

We attend key librarian conferences around the globe and would love to talk to you. You can also find out what special events and workshops we are hosting on our dedicated regional pages.

Conferences and events in: